Previous close | 62.72 |
Open | 62.39 |
Bid | 61.75 x 50000 |
Ask | 61.81 x 50000 |
Day's range | 61.96 - 62.39 |
52-week range | 59.80 - 80.08 |
Volume | |
Avg. volume | 496 |
Market cap | 77.193B |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 187.76 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (4.59%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)